205 related articles for article (PubMed ID: 9605135)
1. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells.
Rus V; Svetic A; Nguyen P; Gause WC; Via CS
J Immunol; 1995 Sep; 155(5):2396-406. PubMed ID: 7650373
[TBL] [Abstract][Full Text] [Related]
3. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation.
Blazar BR; Taylor PA; Fitzsimmons WE; Vallera DA
J Immunol; 1994 Aug; 153(4):1836-46. PubMed ID: 7519216
[TBL] [Abstract][Full Text] [Related]
4. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease.
Krenger W; Snyder KM; Byon JC; Falzarano G; Ferrara JL
J Immunol; 1995 Jul; 155(2):585-93. PubMed ID: 7608537
[TBL] [Abstract][Full Text] [Related]
5. Lethal graft-vs-host disease induced by a class II MHC antigen only disparity is not mediated by cytotoxic T cells.
Thiele DL; Bryde SE; Lipsky PE
J Immunol; 1988 Nov; 141(10):3377-82. PubMed ID: 3053897
[TBL] [Abstract][Full Text] [Related]
6. Effect of graft-versus-host disease on anti-tumor immunity.
Schreiber KL; Forman J
J Immunol; 1990 Mar; 144(5):2018-26. PubMed ID: 1968493
[TBL] [Abstract][Full Text] [Related]
7. Lethal graft-versus-host disease in mice directed to multiple minor histocompatibility antigens: features of CD8+ and CD4+ T cell responses.
Korngold R
Bone Marrow Transplant; 1992 May; 9(5):355-64. PubMed ID: 1352163
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers.
Schlegel PG; Vaysburd M; Chen Y; Butcher EC; Chao NJ
J Immunol; 1995 Oct; 155(8):3856-65. PubMed ID: 7561092
[TBL] [Abstract][Full Text] [Related]
9. Oligoclonal expansion of CTLs directed against a restricted number of dominant minor histocompatibility antigens in hemopoietic chimeras.
Brochu S; Baron C; Hétu F; Roy DC; Perreault C
J Immunol; 1995 Dec; 155(11):5104-14. PubMed ID: 7594519
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of protection from graft-versus-host disease mortality by IL-2. III. Early reductions in donor T cell subsets and expansion of a CD3+CD4-CD8- cell population.
Abraham VS; Sachs DH; Sykes M
J Immunol; 1992 Jun; 148(12):3746-52. PubMed ID: 1534824
[TBL] [Abstract][Full Text] [Related]
11. Peripheral tolerance to host minor histocompatibility antigens in radiation bone marrow chimeras abrogates lethal GVHD while preserving GVL effect.
de la Selle V; Miconnet I; Gilbert D; Bruley-Rosset M
Bone Marrow Transplant; 1995 Jul; 16(1):111-8. PubMed ID: 7581109
[TBL] [Abstract][Full Text] [Related]
12. Different subsets of T cells in the adult mouse bone marrow and spleen induce or suppress acute graft-versus-host disease.
Palathumpat V; Dejbakhsh-Jones S; Holm B; Strober S
J Immunol; 1992 Aug; 149(3):808-17. PubMed ID: 1386094
[TBL] [Abstract][Full Text] [Related]
13. Role of T cell subsets in lethal graft-versus-host disease (GVHD) directed to class I versus class II H-2 differences. II. Protective effects of L3T4+ cells in anti-class II GVHD.
Sprent J; Schaefer M; Korngold R
J Immunol; 1990 Apr; 144(8):2946-54. PubMed ID: 1969878
[TBL] [Abstract][Full Text] [Related]
14. Expansion of intermediate T-cell receptor cells in mice with autoimmune-like graft-versus-host disease.
Ikarashi Y; Abo T; Kawai K; IIai T; Watanabe H; Suzuki K; Matsumoto Y; Omata S; Fujiwara M
Immunology; 1994 Oct; 83(2):205-12. PubMed ID: 7835936
[TBL] [Abstract][Full Text] [Related]
15. Biased liver T cell receptor V beta repertoire in a murine graft-versus-host disease model.
Howell CD; Li J; Roper E; Kotzin BL
J Immunol; 1995 Sep; 155(5):2350-8. PubMed ID: 7650370
[TBL] [Abstract][Full Text] [Related]
16. Donor lymphoid cells of Th2 cytokine phenotype reduce lethal graft versus host disease and facilitate fully allogeneic cell transfers in sublethally irradiated mice.
Fowler DH; Kurasawa K; Smith R; Gress RE
Prog Clin Biol Res; 1994; 389():533-40. PubMed ID: 7700918
[No Abstract] [Full Text] [Related]
17. Immunodominance in the graft-vs-host disease T cell response to minor histocompatibility antigens.
Korngold R; Wettstein PJ
J Immunol; 1990 Dec; 145(12):4079-88. PubMed ID: 2258608
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic and proliferative functions of T lymphocyte clones derived very shortly after allogeneic bone marrow transplantation.
Hamann W; Bruserud O; Patel S; Schmidt H; Ehninger G; Pawelec G
Bone Marrow Transplant; 1991 Aug; 8(2):113-8. PubMed ID: 1933051
[TBL] [Abstract][Full Text] [Related]
19. In vitro characterization of a murine recipient anti-donor effector cell responsible for the development of chronic graft-versus-host disease.
Fast LD
J Immunol; 1991 Sep; 147(6):1731-8. PubMed ID: 1909729
[TBL] [Abstract][Full Text] [Related]
20. The role of cytokines in graft-versus-host reactions and disease.
Jadus MR; Wepsic HT
Bone Marrow Transplant; 1992 Jul; 10(1):1-14. PubMed ID: 1515873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
